The purpose of this trial is to demonstrate at W48 the non-inferiority of a dual nucleoside
analogues strategy with tenofovir (TDF) or tenofovir alafenamide (TAF) plus emtricitabine
(FTC) or lamivudine (3TC) preceded by a 16 week induction period with TDF or TAF plus FTC or
3TC plus an integrase inhibitor (INI) relative to an immediate 2-DR strategy with
dolutegravir plus 3TC in HIV-infected antiretroviral therapy (ARV) naïve participants with
CD4 cells count greater than 300/mm3 and a low viral load defined as plasma HIV RNA strictly
lower than 50 000 cp/mL
Phase:
Phase 3
Details
Lead Sponsor:
ANRS, Emerging Infectious Diseases French National Institute for Health and Medical Research-French National Agency for Research on AIDS and Viral Hepatitis (Inserm-ANRS)
Collaborator:
Institut National de la Santé Et de la Recherche Médicale, France